ROCKET PHARMACEUTICALS, INC. (RCKT) Debt-to-equity % [USD] 2015 - 2024

Historical data

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Rocket Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from 2015 to 2024.
  • Rocket Pharmaceuticals, Inc. Debt-to-equity for the quarter ending March 31, 2024 was 13.2 %, a 6.1% increase year-over-year.
Debt-to-equity, Quarterly (% [USD])
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q1 2024 13.2 +0.76 +6.1% Mar 31, 2024
Q4 2023 13 +1.03 +8.61% Dec 31, 2023
Q3 2023 12.4 +1.39 +12.6% Sep 30, 2023
Q2 2023 13.2 +3.25 +32.7% Jun 30, 2023
Q1 2023 12.5 +2.97 +31.3% Mar 31, 2023
Q4 2022 12 -0.04 -0.33% Dec 31, 2022
Q3 2022 11 -3 -21.4% Sep 30, 2022
Q2 2022 9.94 -8.9 -47.2% Jun 30, 2022
Q1 2022 9.48 -14.9 -61.2% Mar 31, 2022
Q4 2021 12 -15.3 -56% Dec 31, 2021
Q3 2021 14 -16.1 -53.5% Sep 30, 2021
Q2 2021 18.9 -9.19 -32.8% Jun 30, 2021
Q1 2021 24.4 -1.65 -6.33% Mar 31, 2021
Q4 2020 27.3 +0.54 +2.02% Dec 31, 2020
Q3 2020 30.1 +0.69 +2.35% Sep 30, 2020
Q2 2020 28 -2.61 -8.52% Jun 30, 2020
Q1 2020 26.1 -7.32 -21.9% Mar 31, 2020
Q4 2019 26.8 -4.26 -13.7% Dec 31, 2019
Q3 2019 29.4 -2.14 -6.78% Sep 30, 2019
Q2 2019 30.7 -8.89 -22.5% Jun 30, 2019
Q1 2019 33.4 -20.6 -38.1% Mar 31, 2019
Q4 2018 31 -57.8 -65.1% Dec 31, 2018
Q3 2018 31.6 -89.5 -73.9% Sep 30, 2018
Q2 2018 39.5 -63 -61.5% Jun 30, 2018
Q1 2018 54 -13.7 -20.3% Mar 31, 2018
Q4 2017 88.8 +46.8 +112% Dec 31, 2017
Q3 2017 121 +97.7 +418% Sep 30, 2017
Q2 2017 103 +97.2 +1812% Jun 30, 2017
Q1 2017 67.7 +55.1 +438% Mar 31, 2017
Q4 2016 42 +16.8 +66.9% Dec 31, 2016
Q3 2016 23.4 -19.1 -45% Sep 30, 2016
Q2 2016 5.37 Jun 30, 2016
Q1 2016 12.6 Mar 31, 2016
Q4 2015 25.1 Dec 31, 2015
Q3 2015 42.5 Sep 30, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.